-
Product Insights
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2024
Empower your strategies with our Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Vancomycin-resistant Staphylococcus aureus (VRSA) infection occurs when Staphylococcus aureus becomes resistant to the antibiotic vancomycin. Risk factors include taking strong antibiotics the wrong way, which may cause the bacteria to develop resistance to the antibiotics; a weak immune system, and long hospital stays. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat. The Vancomycin-Resistant Staphylococcus...
-
Product Insights
Allergic Bronchopulmonary Aspergillosis - Drugs In Development, 2024
Empower your strategies with our Allergic Bronchopulmonary Aspergillosis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic bronchopulmonary aspergillosis (ABPA) is infection of the lung with Aspergillus fumigatus fungus in those with bronchial asthma, cystic fibrosis, or a compromised immune system. The disease effects are caused by a hypersensitivity reaction to antigens of the Aspergillus species. Clinical manifestations include bronchospasm, pulmonary infiltrates, eosinophilia, and immunologic evidence of allergy to the antigens of Aspergillus species. The Allergic Bronchopulmonary...
-
Product Insights
Cryptococcosis - Drugs In Development, 2024
Empower your strategies with our Cryptococcosis – Drugs In Development, 2024 report and make more profitable business decisions. Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, headache, nausea, and skin rashes. Predisposing factors include a weakened immune system, such as due to HIV infection; high-dose of corticosteroids; cancer chemotherapy; or Hodgkin's disease. Treatment includes antifungal drugs. The Cryptococcosis drugs in development market research report provide comprehensive information on the therapeutics under development for Cryptococcosis, complete with...
-
Product Insights
Dermatophytosis - Drugs In Development, 2024
Empower your strategies with our Dermatophytosis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a red, itchy, scaly, circular rash. Hair loss may occur in the area affected. Symptoms begin four to 14 days after exposure. It is caused by areas of hair, skin, or nails being infected by a dermatophyte, which is most commonly of the Trichophyton genus and less...
-
Product Insights
Japanese Encephalitis - Drugs In Development, 2024
Empower your strategies with our Japanese Encephalitis – Drugs In Development, 2024 report and make more profitable business decisions. Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness, and paralysis. Treatment targets the symptoms with pain relievers and anticonvulsants. The Japanese Encephalitis drugs in development market research report provide comprehensive information...
-
Product Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2024
Empower your strategies with our Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually causes skin infections, but can also cause pneumonia and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea, and abdominal pain. Predisposing factors include weakened immune systems, burns, and surgical wounds. The Methicillin-Susceptible Staphylococcus aureus (MSSA)...
-
Product Insights
Osteomyelitis - Drugs In Development, 2024
Empower your strategies with our Osteomyelitis – Drugs In Development, 2024 report and make more profitable business decisions. Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection, and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes, and peripheral arterial disease. Treatment includes surgery and oral antibiotics....
-
Product Insights
Crimean-Congo Hemorrhagic Fever - Drugs In Development, 2024
Empower your strategies with our Crimean-Congo Hemorrhagic Fever – Drugs In Development, 2024 report and make more profitable business decisions. Crimean Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic viral disease caused by CCHF virus of genus Nairovirus (family Bunyaviridae). It is a deadly hemorrhagic fever that is transmitted by bites from infected ticks (mainly of the Hyalomma genus) or by direct contact with blood or tissues of infected ticks, viraemic patients or viraemic livestock. The Crimean-Congo Hemorrhagic Fever drugs in...
-
Product Insights
Zygomycosis (Mucormycosis) - Drugs In Development, 2024
Empower your strategies with our Zygomycosis (Mucormycosis) – Drugs In Development, 2024 report and make more profitable business decisions. Mucormycosis is previously called as zygomycosis, is a serious but rare fungal infection caused by a group of molds called mucormycetes. This is characterized by tissue infarction and necrosis due to invasion of the vasculature by hyphae. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air The Zygomycosis (Mucormycosis) drugs in development market research report...
-
Product Insights
Cholera - Drugs In Development, 2024
Empower your strategies with our Cholera – Drugs In Development, 2024 report and make more profitable business decisions. Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Symptoms are often mild, they can be very serious. Signs and symptoms of cholera include rapid heart rate, loss of skin elasticity, low...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.